Glucocorticoid-Induced Osteoporosis disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: GLC086 MIFTS: 43	Glucocorticoid-Induced Osteoporosis Categories: Bone diseases
Genes Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Glucocorticoid-Induced Osteoporosis

MalaCards integrated aliases for Glucocorticoid-Induced Osteoporosis:

Name: Glucocorticoid-Induced Osteoporosis ¹² ¹⁵

Steroid-Induced Osteoporosis ¹²

Classifications:

MalaCards categories:
Anatomical: Bone diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:0060343

Sources

Summaries for Glucocorticoid-Induced Osteoporosis

Disease Ontology : ¹² An osteoporosis caused by chronic glucocorticoid use. Glucocorticoids impair the replication, differentiation and function of osteoblasts and induce the apoptosis of mature osteoblasts and osteocytes; the also favor osteoclastogenesis leading to an increase in bone resorption.

MalaCards based summary : Glucocorticoid-Induced Osteoporosis, also known as steroid-induced osteoporosis, is related to synovitis and arthropathy. An important gene associated with Glucocorticoid-Induced Osteoporosis is BGLAP (Bone Gamma-Carboxyglutamate Protein), and among its related pathways/superpathways are Wnt signaling pathway and RANK Signaling in Osteoclasts. The drugs Tocopherol and tannic acid have been mentioned in the context of this disorder. Affiliated tissues include bone, kidney and bone marrow, and related phenotypes are cellular and growth/size/body region

Wikipedia : ⁷⁴ Steroid-induced osteoporosis is osteoporosis arising due to use of glucocorticoids (steroid hormones) -... more...

Sources

Related Diseases for Glucocorticoid-Induced Osteoporosis

Diseases related to Glucocorticoid-Induced Osteoporosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 187)

#	Related Disease	Score	Top Affiliating Genes
1	synovitis	30.4	TNFSF11 TNFRSF11B ACP5
2	arthropathy	30.3	TNFSF11 TNFRSF11B IGF1
3	secondary hyperparathyroidism	30.3	VDR TNFRSF11B PTH CALCA BGLAP ACP5
4	rickets	30.2	VDR PTH CD36 CALCA BGLAP
5	hypervitaminosis d	30.2	VDR PTH CALCA
6	connective tissue disease	30.1	TNFSF11 TNFRSF11B RUNX2 PTH CD36 BGLAP
7	osteomyelitis	30.0	TNFSF11 CALCA BMP2 ACP5
8	nephrolithiasis	29.8	VDR TNFRSF11B PTH BGLAP
9	hyperthyroidism	29.8	PTH IGF1 CALCA BGLAP ACP5
10	periodontitis	29.6	VDR TNFSF11 TNFRSF11B RUNX2 BGLAP ACP5
11	arthritis	29.5	TNFSF11 PTH FOS CSF1 ACP5
12	rheumatoid arthritis	29.5	TNFSF11 TNFRSF11B PTH FOS CSF1 BGLAP
13	osteomalacia	29.4	VDR TNFSF11 SOST PTH CALCA BGLAP
14	osteopetrosis	29.4	TNFSF11 TNFRSF11B RUNX2 CSF1 CALCA BGLAP
15	osteonecrosis	29.2	TNFSF11 TNFRSF11B RUNX2 PTH IGF1 DKK1
16	hyperparathyroidism	29.1	VDR TNFSF11 TNFRSF11B SOST PTH IGF1
17	sclerosteosis	28.7	VDR TNFSF11 TNFRSF11B SOST SFRP1 RUNX2
18	primary hyperparathyroidism	28.6	VDR TNFSF11 TNFRSF11B SOST PTH IGF1
19	osteogenic sarcoma	28.4	VDR TNFSF11 TNFRSF11B RUNX2 PTH IGF1
20	bone resorption disease	28.0	VDR TNFSF11 TNFRSF11B SOST RUNX2 PTH
21	bone disease	27.4	VDR TNFSF11 TNFRSF11B SOST RUNX2 PTH
22	osteoporosis	26.2	VDR TSC22D3 TNFSF11 TNFRSF11B SOST SFRP1
23	bone mineral density quantitative trait locus 8	11.4
24	bone mineral density quantitative trait locus 15	11.4
25	triiodothyronine receptor auxiliary protein	10.5
26	polyarticular onset juvenile idiopathic arthritis	10.5	TNFSF11 TNFRSF11B
27	hypogonadism	10.4
28	hemophilic arthropathy	10.4	TNFSF11 TNFRSF11B
29	autoimmune disease	10.4
30	periodontitis, chronic	10.4	TNFSF11 TNFRSF11B
31	substernal goiter	10.4	PTH CALCA
32	paget disease of bone 5, juvenile-onset	10.4	TNFSF11 TNFRSF11B CALCA
33	temporal arteritis	10.4
34	malignant ovarian brenner tumor	10.3	TNFSF11 PTH CALCA
35	bone giant cell sarcoma	10.3	TNFSF11 CSF1
36	nontoxic goiter	10.3	PTH CALCA BGLAP
37	multicentric reticulohistiocytosis	10.3	TNFSF11 TNFRSF11B CSF1
38	gorham's disease	10.3	TNFSF11 PTH CALCA
39	giant cell reparative granuloma	10.3	TNFSF11 PTH CALCA
40	differentiated thyroid carcinoma	10.3	TNFRSF11B CD36 BGLAP
41	chondrodysplasia, blomstrand type	10.3	TNFSF11 PTH BGLAP
42	thyroid gland disease	10.3	PTH IGF1 CALCA
43	osteopetrosis, autosomal dominant 2	10.3	TNFSF11 BGLAP ACP5
44	dental pulp necrosis	10.3	TNFSF11 BMP2 BGLAP
45	disseminated chorioretinitis	10.3	TNFSF11 TNFRSF11B
46	goiter	10.3	IGF1 CALCA BGLAP
47	villonodular synovitis	10.3	TNFSF11 CSF1 ACP5
48	craniometaphyseal dysplasia, autosomal dominant	10.3	TNFSF11 RUNX2 BGLAP
49	periapical periodontitis	10.3	TNFSF11 TNFRSF11B ACP5
50	bone mineral density quantitative trait locus 3	10.3

Graphical network of the top 20 diseases related to Glucocorticoid-Induced Osteoporosis:

Sources

Symptoms & Phenotypes for Glucocorticoid-Induced Osteoporosis

MGI Mouse Phenotypes related to Glucocorticoid-Induced Osteoporosis:

⁴⁵ (show all 14)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cellular	MP:0005384	10.4	AXIN2 BGLAP BMP2 CD36 CSF1 DKK1
2	growth/size/body region	MP:0005378	10.38	AXIN2 BMP2 CD36 CSF1 DKK1 FOS
3	craniofacial	MP:0005382	10.29	AXIN2 BMP2 CSF1 DKK1 FOS PAX5
4	cardiovascular system	MP:0005385	10.28	AXIN2 BMP2 CD36 CSF1 IGF1 PAX5
5	hematopoietic system	MP:0005397	10.28	BGLAP BMP2 CD36 CSF1 FOS IGF1
6	endocrine/exocrine gland	MP:0005379	10.27	AXIN2 BGLAP CD36 CSF1 FOS IGF1
7	homeostasis/metabolism	MP:0005376	10.25	BGLAP BMP2 CD36 CSF1 DKK1 FOS
8	immune system	MP:0005387	10.21	BGLAP BMP2 CD36 CSF1 FOS IGF1
9	limbs/digits/tail	MP:0005371	10.13	AXIN2 BMP2 CSF1 DKK1 FOS IGF1
10	mortality/aging	MP:0010768	10.1	AXIN2 BMP2 CD36 CSF1 DKK1 FOS
11	hearing/vestibular/ear	MP:0005377	10	BMP2 CSF1 FOS IGF1 PAX5 TNFRSF11B
12	nervous system	MP:0003631	9.9	AXIN2 BMP2 CD36 CSF1 DKK1 FOS
13	reproductive system	MP:0005389	9.7	AXIN2 BGLAP BMP2 CSF1 FOS IGF1
14	skeleton	MP:0005390	9.53	AXIN2 BGLAP BMP2 CD36 CSF1 DKK1

Sources

Drugs & Therapeutics for Glucocorticoid-Induced Osteoporosis

Drugs for Glucocorticoid-Induced Osteoporosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 71)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Tocopherol

Approved, Investigational

Phase 4

1406-66-2, 54-28-4

14986

tannic acid

Approved

Phase 4

1401-55-4

Benzocaine

Approved, Investigational

Phase 4

94-09-7, 1994-09-7

2337

Teriparatide

Approved, Investigational

Phase 4

52232-67-4

16133850

Risedronate

Approved, Investigational

Phase 4

105462-24-6

5245

Parathyroid hormone

Approved, Investigational

Phase 4

9002-64-6

Prednisone

Approved, Vet_approved

Phase 4

53-03-2

5865

Etidronic acid

Approved

Phase 4

2809-21-4, 7414-83-7

3305

Denosumab

Approved

Phase 4

615258-40-7

Alendronate

Approved

Phase 4

66376-36-1, 121268-17-5

2088

Vitamin D

Approved, Nutraceutical, Vet_approved

Phase 4

1406-16-2

Vitamin D3

Approved, Nutraceutical

Phase 4

67-97-0

5280795 6221

Vitamin E

Approved, Nutraceutical, Vet_approved

Phase 4

59-02-9

14985

Alfacalcidol

Approved, Nutraceutical

Phase 4

41294-56-8

5282181

Tocotrienol

Investigational

Phase 4

6829-55-6

Calciferol

Phase 4

Tocotrienols

Phase 4

Tocopherols

Phase 4

Trace Elements

Phase 4

Vitamins

Phase 4

Hydroxycholecalciferols

Phase 4

Nutrients

Phase 4

Micronutrients

Phase 4

Hormones

Phase 4

Calcium, Dietary

Phase 4

Ibandronic Acid

Phase 4

Hormone Antagonists

Phase 4

calcium channel blockers

Phase 4

glucocorticoids

Phase 4

Calcium

Nutraceutical

Phase 4

7440-70-2

271

Ferrous fumarate

Approved

Phase 3

141-01-5

Estradiol

Approved, Investigational, Vet_approved

Phase 3

50-28-2

5757

Norethindrone

Approved

Phase 3

68-22-4

6230

Ethinyl Estradiol

Approved

Phase 3

57-63-6

5991

Polyestradiol phosphate

Approved

Phase 3

28014-46-2

Genistein

Investigational

Phase 2, Phase 3

446-72-0

5280961

Protein Kinase Inhibitors

Phase 2, Phase 3

Phytoestrogens

Phase 2, Phase 3

Estrogens

Phase 3

Estradiol 17 beta-cypionate

Phase 3

Contraceptive Agents

Phase 3

Contraceptives, Oral

Phase 3

Contraceptives, Oral, Hormonal

Phase 3

Estradiol 3-benzoate

Phase 3

Contraceptives, Oral, Combined

Phase 3

Norethindrone acetate, ethinyl estradiol, ferrous fumarate drug combination

Phase 3

Norethindrone Acetate

Phase 3

Norinyl

Phase 3

Diphosphonates

Phase 3

Immunoglobulins

Phase 3

Interventional clinical trials:

(show all 33)

#	Name	Status	NCT ID	Phase	Drugs
1	Maintenance of Vitamin D Sufficiency With Oral Vitamin D Supplementation in Malaysian Women of Malay and Indian Ethnicity With Post Menopausal Osteoporosis	Unknown status	NCT02389179	Phase 4	Vitamin D3
2	Denosumab in Current Users of Bisphosphonates for Glucocorticoid-induced Osteoporosis: a Randomized Controlled Trial	Completed	NCT01465568	Phase 4	Denosumab;bisphosphonates
3	Efficacy of Monthly Ibandronate in Women With Rheumatoid Arthritis and Reduced Bone Mineral Density Receiving Long-term Glucocorticoids	Completed	NCT01287533	Phase 4	Ibandronate;Placebo
4	A Randomized, Double-blind Study to Evaluate the Effect of Once Monthly Bonviva on Lumbar Bone Mineral Density in the Prevention of Glucocorticoid-induced Osteoporosis in Post-menopausal Women	Completed	NCT00545051	Phase 4	Placebo;ibandronate
5	Denosumab Versus Oral Bisphosphonate (Alendronate) for Osteoporosis in Long-term Glucocorticoid Users: an Open Randomized Controlled Trial	Completed	NCT03005678	Phase 4	Denosumab;Alendronate
6	HRT and/or Etidronate in the Prevention and Treatment of Osteoporosis and Fractures in Post-Menopausal Patients With Asthma Receiving Long-Term Oral and/or Inhaled Glucocorticoids:a Randomised Factorial Trial	Completed	NCT00376662	Phase 4	Hormone Replacement Therapy and Etidronate
7	Can Risedronate and Parathyroid Hormone Reverse Glucocorticoid Induced Osteoporosis?	Completed	NCT00221299	Phase 4	Risedronate;Parathyroid Hormone
8	Steroid Induced Osteoporosis in Patients With Systemic Lupus Erythematosus-Prevalence,Risk Factors and Treatment	Completed	NCT00668330	Phase 4	Ibandronate+alfacalcidol+calcium;placebo ibandronate+alfacalcidol+calcium
9	Romosozumab Versus Denosumab for Osteoporosis in Long-term Glucocorticoid Users: an Open Randomized Controlled Trial	Not yet recruiting	NCT04091243	Phase 4	Romosozumab
10	Denosumab (DMAB) Discontinuation And Switching In Glucocorticoid-Induced Osteoporosis (GIOP): A Pilot Study	Not yet recruiting	NCT04177940	Phase 4	DMAB Discontinuation and Switching
11	Randomised, Double Blind, Placebo Controlled Trial to Ascertain the Efficacy and Safety of Intravenous Zoledronic Acid in Adult Patients With Cystic Fibrosis.	Withdrawn	NCT01702415	Phase 4	Zoledronic acid;Placebo
12	Metabolic, Endocrine, and Central Effects of Genistein Aglycone in Glucocorticoid Induced Osteoporosis	Unknown status	NCT03040531	Phase 2, Phase 3	Alendronate Oral Tablet
13	Comparison of the Effects of Teriparatide With Those of Alendronate Sodium on Lumbar Spine Bone Mineral Density in Glucocorticoid-Induced Osteoporosis	Completed	NCT00051558	Phase 3	Teriparatide;Alendronate Sodium;Placebo;Placebo
14	Prevention of Glucocorticoid-Induced Osteoporosis in Patients With Rheumatic Diseases. The STOP-Study: a Randomized Placebo Controlled Trial With Alendronate Versus Alfacalcidol.	Completed	NCT00138983	Phase 3	Alendronate versus alfacalcidol (1-alpha OH vitamin D)
15	A Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy and Safety of Denosumab Compared With Risedronate in Glucocorticoid-treated Individuals	Completed	NCT01575873	Phase 3	Denosumab;Placebo for risendronate;Risendronate;Placebo for denosumab
16	Comparison of the Effects of Teriparatide With Those of Risedronate on Lumbar Spine vBMD in Glucocorticoid-Induced Osteoporosis in Men	Completed	NCT00503399	Phase 3	Teriparatide;Risedronate
17	Safety of Estrogens in Lupus Erythematosus - National Assessment (SELENA): Oral Contraceptives	Completed	NCT00000420	Phase 3	Ortho-Novum 777
18	A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Denosumab in Pediatric Subjects With Glucocorticoid-induced Osteoporosis	Recruiting	NCT03164928	Phase 3	Denosumab
19	Efficacy of Denosumab and Zoledronic Acid in the Treatment of Idiopathic Inflammatory Myopathies Related Reduced Bone Mineral Density: a Prospective Controlled Trial	Not yet recruiting	NCT04034199	Phase 3	Denosumab;Zoledronic Acid
20	Can PTH Reverse Glucocorticoid-induced Osteoporosis	Completed	NCT00004993	Phase 2	Parathyroid hormone (hPTH 1-34)
21	Randomized Controlled Trial of Teriparatide for the Treatment of Idiopathic Osteoporosis in Premenopausal Women	Completed	NCT01440803	Phase 2	Teriparatide;Saline Placebo
22	Alendronate Versus Placebo for Idiopathic Juvenile Osteoporosis	Completed	NCT00001720	Phase 2	Alendronate
23	Denosumab (A Monoclonal Antibody to Receptor Activator of Nuclear Factor-Kappa B Ligand (RANKL) in Crohn's Disease	Completed	NCT02321280	Phase 1, Phase 2	Denosumab
24	The Effects of 12-months of Denosumab on Bone Density, Quality and Strength in Prevalent Kidney Transplant Recipients	Recruiting	NCT03960554	Phase 2	Denosumab Inj 60 mg/ml
25	Prevention of Steroid-Induced Osteoporosis in Children	Terminated	NCT00022841	Phase 1, Phase 2	Pamidronate
26	Eldecalcitol for GLucocorticoid Induced OsteopoRosIs Versus Alfacalcidol	Unknown status	NCT01974167		Eldecalcitol;Alfacalcidol
27	Clinical Trial on the Efficacy of Raloxifene on Disease Activity and Glucocorticoid-induced Osteoporosis in Postmenopausal Women With Rheumatoid Arthritis	Unknown status	NCT02982083		Raloxifene hydrochloride;Placebo Oral Tablet
28	Steroid Induced Osteoporosis in the Pediatric Population Ancillary Study- Osteonecrosis in Children With Acute Lymphoblastic Leukemia	Unknown status	NCT01104324
29	Prospective,Non-interventional Study Investigating Possible Correlation Between Adherence to Postmenopausal and Steroid Induced Osteoporosis Treatment and Physicians' Perception Regarding Osteoporosis Medication	Completed	NCT02472782		Teriparatide
30	Osteoporosis Prevention Among People With Rheumatoid Arthritis Receiving Oral Glucocorticoid Therapy	Completed	NCT00609830
31	Steroid-Induced Osteoporosis in the Pediatric Population - Canadian Incidence Study (STOPP-CIS)	Completed	NCT01663129
32	Non-interventional Clinical Trial to Establish a Glucocorticoid-induced Osteoporosis Databank for Patients With Chronic Inflammatory Rheumatic Diseases or Psoriasis and Therapy With Glucocorticoids	Recruiting	NCT02719314		Glucocorticoid treatment
33	Glucocorticoids Promote Osteoclast Survival	Terminated	NCT00572299		alendronate

Search NIH Clinical Center for Glucocorticoid-Induced Osteoporosis

Sources

Genetic Tests for Glucocorticoid-Induced Osteoporosis

Sources

Anatomical Context for Glucocorticoid-Induced Osteoporosis

MalaCards organs/tissues related to Glucocorticoid-Induced Osteoporosis:

⁴⁰

Bone, Kidney, Bone Marrow, Lung, Testes, Heart, Appendix

Sources

Publications for Glucocorticoid-Induced Osteoporosis

Articles related to Glucocorticoid-Induced Osteoporosis:

(show top 50) (show all 1207)

#	Title	Authors	PMID	Year
1	Liquiritigenin reduces osteoclast activity in zebrafish model of glucocorticoid-induced osteoporosis. ⁶¹	Carnovali M...Mariotti M	32534995	2020
2	Extraction, purification and anti-osteoporotic activity of a polysaccharide from Epimedium brevicornum Maxim. in vitro. ⁶¹	Zheng H...Wei J	31751710	2020
3	Pinocembrin alleviates glucocorticoid-induced apoptosis by activating autophagy via suppressing the PI3K/Akt/mTOR pathway in osteocytes. ⁶¹	Wang XY...Yan ZQ	32470335	2020
4	Nicotinamide mononucleotide attenuates glucocorticoid‑induced osteogenic inhibition by regulating the SIRT1/PGC‑1α signaling pathway. ⁶¹	Huang RX...Tao J	32377728	2020
5	Investigation of bone matrix composition, architecture and mechanical properties reflect structure-function relationship of cortical bone in glucocorticoid induced osteoporosis. ⁶¹	Xi L...Fang D	32224161	2020
6	Trabecular bone score improves fracture risk assessment in glucocorticoid-induced osteoporosis. ⁶¹	Florez H...Peris P	31628810	2020
7	Siglec-15-targeting therapy protects against glucocorticoid-induced osteoporosis of growing skeleton in juvenile rats. ⁶¹	Sato D...Iwasaki N	32217159	2020
8	Effects of anti-osteoporosis drugs against dexamethasone-induced osteoporosis-like phenotype using a zebrafish scale-regeneration model. ⁶¹	Saito Y...Hara H	32220570	2020
9	Effects of short- and long-term glucocorticoid-induced osteoporosis on plasma metabolome and lipidome of ovariectomized sheep. ⁶¹	Cabrera D...Fraser K	32503480	2020
10	Bromodomain Protein BRD4 Accelerates Glucocorticoid Dysregulation of Bone Mass and Marrow Adiposis by Modulating H3K9 and Foxp1. ⁶¹	Wang FS...Lian WS	32575577	2020
11	History of risedronate. ⁶¹	McClung MR...Ebetino FH	32387834	2020
12	Glucocorticoids induce osteoporosis mediated by glucocorticoid receptor-dependent and -independent pathways. ⁶¹	Jiang Y...Rong X	32044718	2020
13	History of etidronate. ⁶¹	Watts NB...Valent D	31911206	2020
14	In vitro and in vivo studies using non-traditional bisphosphonates. ⁶¹	Plotkin LI...Balanta-Melo J	32112989	2020
15	Glucocorticoid-induced autophagy and apoptosis in bone. ⁶¹	Wang T...He C	32157482	2020
16	Treatment options for glucocorticoid-induced osteoporosis. ⁶¹	Chiodini I...Gennari L	32004105	2020
17	Involvement of the Gut Microbiota and Barrier Function in Glucocorticoid-Induced Osteoporosis. ⁶¹	Schepper JD...McCabe LR	31886921	2020
18	Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment. ⁶¹	Chotiyarnwong P...McCloskey EV	32286516	2020
19	Views on glucocorticoid therapy in rheumatology: the age of convergence. ⁶¹	Buttgereit F	32076129	2020
20	Dexras1 plays a pivotal role in maintaining the equilibrium between adipogenesis and osteogenesis. ⁶¹	Seok JW...Kim JW	32335074	2020
21	Hesperetin alleviated glucocorticoid-induced inhibition of osteogenic differentiation of BMSCs through regulating the ERK signaling pathway. ⁶¹	Liu L...Yu D	32253606	2020
22	Eldecalcitol is superior to alfacalcidol in maintaining bone mineral density in glucocorticoid-induced osteoporosis patients (e-GLORIA). ⁶¹	Matsumoto T...Soen S	32140784	2020
23	Tuna Bone Powder Alleviates Glucocorticoid-Induced Osteoporosis via Coregulation of the NF-κB and Wnt/β-Catenin Signaling Pathways and Modulation of Gut Microbiota Composition and Metabolism. ⁶¹	Li J...Su X	31953894	2020
24	Management of glucocorticoid-related osteoporotic vertebral fracture. ⁶¹	Wong SPY...Mok CC	32226826	2020
25	Reduction of fibrillar strain-rate sensitivity in steroid-induced osteoporosis linked to changes in mineralized fibrillar nanostructure. ⁶¹	Xi L...Gupta HS	31726107	2020
26	Integrated metabolomic analysis for intervention effects of Gushudan on glucocorticoid-induced osteoporostic rat plasma based on RP/HILIC-UHPLC-Q-Orbitrap HRMS. ⁶¹	Yuan X...Xiong Z	31874173	2020
27	A retrospective database study of oral corticosteroid and bisphosphonate prescribing patterns in England. ⁶¹	Chalitsios CV...McKeever TM	32054843	2020
28	Ethyl Acetate Fraction of Aqueous Extract of Lentinula edodes Inhibits Osteoclastogenesis by Suppressing NFATc1 Expression. ⁶¹	Lee H...Kim K	32079267	2020
29	The therapeutic efficacy of denosumab for the loss of bone mineral density in glucocorticoid-induced osteoporosis: a meta-analysis. ⁶¹	Yamaguchi Y...Kumanogoh A	32373775	2020
30	Icariin Alleviates Glucocorticoid-Induced Osteoporosis through EphB4/Ephrin-B2 Axis. ⁶¹	Huang M...Peng R	32508946	2020
31	A chitosan film containing quercetin-loaded transfersomes for treatment of secondary osteoporosis. ⁶¹	Pandit AP...Mute VM	31942700	2020
32	Minodronate combined with alfacalcidol versus alfacalcidol alone for glucocorticoid-induced osteoporosis: a multicenter, randomized, comparative study. ⁶¹	Soen S...Matsumoto T	31970477	2020
33	Evaluation of the Implementation of Guidelines on the Treatment of Osteoporosis in Patients with Rheumatoid Arthritis. ⁶¹	Malochet-Guinamand S...Dougados M	30877214	2020
34	Integrative Analysis for Elucidating Transcriptomics Landscapes of Glucocorticoid-Induced Osteoporosis. ⁶¹	Ying X...Liu H	32373610	2020
35	Off-label uses of denosumab in metabolic bone diseases. ⁶¹	Polyzos SA...Anastasilakis AD	31454537	2019
36	Ferulic acid, a natural polyphenol, protects against osteoporosis by activating SIRT1 and NF-κB in neonatal rats with glucocorticoid-induced osteoporosis. ⁶¹	Hou T...Yang X	31634777	2019
37	Extracellular vesicles from endothelial progenitor cells prevent steroid-induced osteoporosis by suppressing the ferroptotic pathway in mouse osteoblasts based on bioinformatics evidence. ⁶¹	Lu J...Fang S	31695092	2019
38	Bisphosphonates as a First-Line Treatment for Glucocorticoid-Induced Osteoporosis: Comment on the Article by Saag et al. ⁶¹	Gonzalez-Rodriguez E...Lamy O	31215777	2019
39	Where Does Denosumab Stand in the Treatment of Glucocorticoid-Induced Osteoporosis? Comment on the Article by Saag et al. ⁶¹	Chattopadhyay A...Dhir V	31216125	2019
40	High bisphosphonate treatment rates and the prevalence of atypical femoral fractures in patients with systematic lupus erythematosus: a single-center retrospective study performed in Japan. ⁶¹	Sato H...Narita I	31385078	2019
41	circRNA_0006393 promotes osteogenesis in glucocorticoid‑induced osteoporosis by sponging miR‑145‑5p and upregulating FOXO1. ⁶¹	Wang XB...Shi SB	31322188	2019
42	Liraglutide increases bone formation and inhibits bone resorption in rats with glucocorticoid-induced osteoporosis. ⁶¹	Yang L...Zhong X	30955181	2019
43	Management of glucocorticoid-induced osteoporosis: What is new? ⁶¹	Compston J	31478605	2019
44	Preventative effects of metformin on glucocorticoid-induced osteoporosis in rats. ⁶¹	Zhao J...Zuo L	30706148	2019
45	Hydrogen sulfide is a novel regulator implicated in glucocorticoids-inhibited bone formation. ⁶¹	Ma J...Ye T	31525733	2019
46	Abaloparatide increases bone mineral density and bone strength in ovariectomized rabbits with glucocorticoid-induced osteopenia. ⁶¹	Chandler H...Lanske B	31053927	2019
47	Tetracycline Analogs Inhibit Osteoclast Differentiation by Suppressing MMP-9-Mediated Histone H3 Cleavage. ⁶¹	Kim Y...Kim K	31430857	2019
48	11β-HSD1 plays a critical role in trabecular bone loss associated with systemic glucocorticoid therapy. ⁶¹	Fenton CG...Hardy RS	31420008	2019
49	3T chemical shift-encoded MRI: Detection of altered proximal femur marrow adipose tissue composition in glucocorticoid users and validation with magnetic resonance spectroscopy. ⁶¹	Martel D...Chang G	30548522	2019
50	Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four-Month Randomized, Double-Blind, Double-Dummy Trial. ⁶¹	Saag KG...Lems WF	30816640	2019

Sources

Genes for Glucocorticoid-Induced Osteoporosis

Genes related to Glucocorticoid-Induced Osteoporosis (0 elite genes):

(show all 20)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	BGLAP	Bone Gamma-Carboxyglutamate Protein	Protein Coding	15.02	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
2	CALCA	Calcitonin Related Polypeptide Alpha	Protein Coding	14.4	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
3	TNFSF11	TNF Superfamily Member 11	Protein Coding	14.31	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
4	TNFRSF11B	TNF Receptor Superfamily Member 11b	Protein Coding	14.3	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
5	PTH	Parathyroid Hormone	Protein Coding	14.06	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
6	RUNX2	RUNX Family Transcription Factor 2	Protein Coding	13.35	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
7	ACP5	Acid Phosphatase 5, Tartrate Resistant	Protein Coding	13.25	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
8	DKK1	Dickkopf WNT Signaling Pathway Inhibitor 1	Protein Coding	13.02	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
9	BMP2	Bone Morphogenetic Protein 2	Protein Coding	12.53	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
10	SFRP1	Secreted Frizzled Related Protein 1	Protein Coding	11.96	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
11	IGF1	Insulin Like Growth Factor 1	Protein Coding	11.94	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
12	TSC22D3	TSC22 Domain Family Member 3	Protein Coding	11.62	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
13	VDR	Vitamin D Receptor	Protein Coding	11.19	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
14	CSF1	Colony Stimulating Factor 1	Protein Coding	11.18	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
15	FOS	Fos Proto-Oncogene, AP-1 Transcription Factor Subunit	Protein Coding	10.41	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
16	AXIN2	Axin 2	Protein Coding	10.02	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
17	MIR106B	MicroRNA 106b	RNA Gene	9.87	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
18	PAX5	Paired Box 5	Protein Coding	9.39	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
19	SOST	Sclerostin	Protein Coding	7.58	DISEASES inferred ¹⁵
20	CD36	CD36 Molecule	Protein Coding	6.83	GeneCards inferred via : Publications (show sections)

Sources

Variations for Glucocorticoid-Induced Osteoporosis

Sources

Expression for Glucocorticoid-Induced Osteoporosis

Search GEO for disease gene expression data for Glucocorticoid-Induced Osteoporosis.

Sources

Pathways for Glucocorticoid-Induced Osteoporosis

Pathways related to Glucocorticoid-Induced Osteoporosis according to GeneCards Suite gene sharing:

(show all 21)

#	Super pathways	Score	Top Affiliating Genes
1	Wnt signaling pathway ³⁶ Show member pathways Wnt Signaling Pathways ⁶⁴	12.31	SOST SFRP1 DKK1 AXIN2
2	RANK Signaling in Osteoclasts ⁶³ Show member pathways Apoptosis and survival APRIL and BAFF signaling ²² APRIL Pathway ⁶³ BAFF in B-Cell Signaling ⁶³ RANK Pathway ⁶³ RANKL/RANK (Receptor activator of NFKB (ligand)) Signaling Pathway ¹	12.29	TNFSF11 TNFRSF11B FOS ACP5
3	Wnt / Hedgehog / Notch ⁴	12.09	SFRP1 PAX5 DKK1 AXIN2
4	Osteoclast differentiation ³⁶	11.91	TNFSF11 TNFRSF11B FOS CSF1 ACP5
5	Mesenchymal Stem Cells and Lineage-specific Markers ⁶⁴	11.74	RUNX2 PTH IGF1 BMP2 BGLAP
6	Parathyroid hormone synthesis, secretion and action ³⁶	11.73	VDR TNFSF11 SOST RUNX2 PTH FOS
7	Rheumatoid arthritis ³⁶	11.69	TNFSF11 PTH FOS CSF1 ACP5
8	Regulation of nuclear SMAD2/3 signaling ¹	11.62	VDR RUNX2 FOS
9	Endochondral Ossification ¹	11.53	RUNX2 PTH IGF1
10	Differentiation Pathway ¹	11.42	TNFSF11 IGF1 DKK1 CSF1
11	FGF signaling pathway ¹	11.36	RUNX2 FOS BGLAP
12	Development_Hedgehog and PTH signaling pathways in bone and cartilage development ²²	11.02	VDR TNFSF11 RUNX2 PTH FOS BGLAP
13	Negative regulation of TCF-dependent signaling by WNT ligand antagonists ⁶⁵ Show member pathways Misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling ⁶⁵	10.99	SOST SFRP1 DKK1
14	Transcription_Role of VDR in regulation of genes involved in osteoporosis ²²	10.93	VDR TNFSF11 TNFRSF11B RUNX2 PTH IGF1
15	G-protein signaling_Rap2B regulation pathway ²²	10.88	TNFSF11 IGF1 FOS CSF1 BMP2
16	Osteoclast Signaling ¹	10.86	TNFSF11 TNFRSF11B ACP5
17	LDL Oxidation in Atherogenesis ⁶³	10.8	CSF1 CD36
18	BMP2-WNT4-FOXO1 Pathway in Human Primary Endometrial Stromal Cell Differentiation ¹	10.75	SFRP1 DKK1 BMP2
19	Osteoblast Signaling ¹	10.7	TNFSF11 TNFRSF11B PTH BGLAP
20	Development of pulmonary dendritic cells and macrophage subsets ¹	10.68	RUNX2 CSF1
21	Vitamin D Metabolism ¹	10.55	VDR PTH

Sources

GO Terms for Glucocorticoid-Induced Osteoporosis

Cellular components related to Glucocorticoid-Induced Osteoporosis according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular region	GO:0005576	9.7	TNFSF11 TNFRSF11B SOST SFRP1 PTH IGF1
2	extracellular space	GO:0005615	9.44	TNFSF11 TNFRSF11B SOST SFRP1 PTH MIR106B

Biological processes related to Glucocorticoid-Induced Osteoporosis according to GeneCards Suite gene sharing:

(show all 45)

#	Name	GO ID	Score	Top Affiliating Genes
1	multicellular organism development	GO:0007275	10.19	VDR TNFSF11 SFRP1 PAX5 DKK1 BMP2
2	negative regulation of transcription by RNA polymerase II	GO:0000122	10.14	VDR PTH PAX5 DKK1 CD36 BMP2
3	negative regulation of transcription, DNA-templated	GO:0045892	10.09	VDR SFRP1 RUNX2 CALCA BMP2
4	positive regulation of transcription by RNA polymerase II	GO:0045944	10.08	VDR TNFSF11 RUNX2 PTH PAX5 IGF1
5	positive regulation of transcription, DNA-templated	GO:0045893	10.05	SOST SFRP1 RUNX2 IGF1 FOS BMP2
6	cytokine-mediated signaling pathway	GO:0019221	9.99	TNFSF11 FOS CSF1 CD36
7	Wnt signaling pathway	GO:0016055	9.96	SOST SFRP1 DKK1 AXIN2
8	response to drug	GO:0042493	9.92	TNFRSF11B SFRP1 PTH FOS BGLAP
9	aging	GO:0007568	9.91	PAX5 FOS CALCA BGLAP
10	cellular calcium ion homeostasis	GO:0006874	9.87	VDR PTH CALCA
11	animal organ morphogenesis	GO:0009887	9.86	VDR TNFSF11 PAX5 BMP2
12	cellular response to growth factor stimulus	GO:0071363	9.83	SFRP1 BMP2 BGLAP
13	response to mechanical stimulus	GO:0009612	9.81	SOST FOS BGLAP
14	positive regulation of osteoblast differentiation	GO:0045669	9.8	RUNX2 IGF1 BMP2
15	negative regulation of gene expression	GO:0010629	9.8	VDR SFRP1 MIR106B IGF1 CD36 BMP2
16	negative regulation of Wnt signaling pathway	GO:0030178	9.79	SOST SFRP1 DKK1
17	positive regulation of cell death	GO:0010942	9.77	DKK1 CD36 AXIN2
18	negative regulation of BMP signaling pathway	GO:0030514	9.77	SOST SFRP1 DKK1
19	negative regulation of canonical Wnt signaling pathway	GO:0090090	9.77	SOST SFRP1 DKK1 BMP2 AXIN2
20	cellular response to amyloid-beta	GO:1904646	9.76	MIR106B IGF1 CD36
21	osteoblast differentiation	GO:0001649	9.76	SFRP1 RUNX2 BMP2 BGLAP
22	positive regulation of gene expression	GO:0010628	9.76	VDR TNFSF11 RUNX2 IGF1 DKK1 CSF1
23	bone mineralization	GO:0030282	9.74	BMP2 BGLAP AXIN2
24	negative regulation of bone resorption	GO:0045779	9.69	TNFRSF11B CALCA
25	positive regulation of ossification	GO:0045778	9.69	PTH BMP2
26	cellular response to BMP stimulus	GO:0071773	9.69	SFRP1 RUNX2 BMP2
27	negative regulation of peptidyl-tyrosine phosphorylation	GO:0050732	9.68	SFRP1 MIR106B
28	regulation of osteoclast differentiation	GO:0045670	9.68	TNFSF11 BGLAP
29	positive regulation of macrophage differentiation	GO:0045651	9.68	CSF1 CALCA
30	cellular response to vitamin D	GO:0071305	9.67	SFRP1 BGLAP
31	intestinal absorption	GO:0050892	9.67	VDR CD36
32	regulation of ossification	GO:0030278	9.67	RUNX2 CSF1
33	positive regulation of cell-matrix adhesion	GO:0001954	9.67	SFRP1 CSF1 CD36
34	negative regulation of cardiac muscle cell differentiation	GO:2000726	9.65	DKK1 BMP2
35	response to gravity	GO:0009629	9.65	FOS BGLAP
36	positive regulation of transcription from RNA polymerase II promoter involved in cellular response to chemical stimulus	GO:1901522	9.64	RUNX2 BMP2
37	regulation of odontogenesis of dentin-containing tooth	GO:0042487	9.62	RUNX2 BMP2
38	bone mineralization involved in bone maturation	GO:0035630	9.61	IGF1 BMP2
39	bone resorption	GO:0045453	9.61	TNFSF11 PTH ACP5
40	positive regulation of osteoclast differentiation	GO:0045672	9.58	TNFSF11 FOS CSF1
41	negative regulation of ossification	GO:0030279	9.56	SOST SFRP1 DKK1 CALCA
42	Wnt signaling pathway involved in somitogenesis	GO:0090244	9.55	SFRP1 DKK1
43	osteoclast proliferation	GO:0002158	9.54	TNFSF11 CSF1
44	ossification	GO:0001503	9.43	TNFSF11 SOST RUNX2 BMP2 BGLAP ACP5
45	skeletal system development	GO:0001501	9.17	VDR TNFRSF11B RUNX2 PTH IGF1 BMP2

Molecular functions related to Glucocorticoid-Induced Osteoporosis according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	DNA-binding transcription factor activity, RNA polymerase II-specific	GO:0000981	9.63	VDR TSC22D3 RUNX2 PTH PAX5 FOS
2	co-receptor binding	GO:0039706	9.26	DKK1 BMP2
3	cytokine activity	GO:0005125	9.26	TNFSF11 TNFRSF11B CSF1 BMP2
4	growth factor activity	GO:0008083	8.92	IGF1 DKK1 CSF1 BMP2

Sources

Sources for Glucocorticoid-Induced Osteoporosis

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ LncRNADisease

³⁹ LOVD

⁴⁰ MalaCards

⁴¹ MedGen

⁴² MedlinePlus

⁴³ MeSH

⁴⁴ MESH via Orphanet

⁴⁵ MGI

⁴⁶ miR2Disease

⁴⁷ NCBI Bookshelf

⁴⁸ NCI

⁴⁹ NCIt

⁵⁰ NDF-RT

⁵¹ NIH Clinical Center

⁵² NIH Rare Diseases

⁵³ NINDS

⁵⁴ Novoseek

⁵⁵ Novus Biologicals

⁵⁶ OMIM

⁵⁷ OMIM via Orphanet

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubMed

⁶² PubMed Health

⁶³ QIAGEN

⁶⁴ R&D Systems

⁶⁵ Reactome

⁶⁶ Sino Biological

⁶⁷ SNOMED-CT

⁶⁸ SNOMED-CT via HPO

⁶⁹ TGDB

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ Wikipedia